Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: Assessment of pharmacokinetic changes and safety following multiple oral doses

British Journal of Clinical Pharmacology, Supplement

Volumn 58, Issue 1, 2004, Pages 41-49

  Okereke, Chukwuemeka S ^a   Kirby, Louis ^b   Kurnar, Dinesh ^a   Cullen, Edward I ^a,c   Pratt, Raymond D ^a,d   Hahne, William A ^a,e  

^a EISAI INC   (United States)

^b Pivotal Research Centers   (United States)

^c Shire Pharmaceut Development Inc ^*

^d SHIRE   (United States)

^e CURAGEN CORPORATION   (United States)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Donepezil; Levodopa; Parkinson's disease; Pharmacokinetics

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO; CHOLINESTERASE;

ABDOMINAL PAIN; ABRASION; ADULT; AGED; ALZHEIMER DISEASE; ARTHRALGIA; ARTICLE; ASTHENIA; ATAXIA; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; NEUROTOXICITY; OPEN STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; STEADY STATE; SWEATING; TREATMENT OUTCOME; TREMOR; UNPLEASANT DREAM; VOMITING; CHOLINERGIC ACTIVITY; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; DRUG CONCENTRATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG HALF LIFE; DRUG MONITORING; DRUG RESPONSE; DRUG STABILITY; DRUG TOLERABILITY; MOTOR DYSFUNCTION; MULTIPLE DRUG DOSE;

EID: 8844228178     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.01799.x     Document Type: Article

References (36)

1. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
2. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977; 1: 189.
3. Bowen DM, Benton JS, Spillane JA, Smith CC, Allen SJ. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci 1982; 57: 191-202.
4. Rogers SL, Yamanishi Y, Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. In Cholinergic Basis for Alzheimer Therapy, eds Becker, R, Giacobini, E. Boston: Birkhäuser, 1991, 314-20.
5. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-31.
6. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45.
7. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
8. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P; Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95.
9. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; "312" Study Group. A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8.
10. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20.
11. Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 7-12.
12. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki K, Morishita N. Pharmacokinetics of E2020 - a new compound for Alzheimer's disease, in healthy male volunteers, Int J Clin Pharmacol Ther Toxicol 1993; 31: 223-9.
13. ARICEPT® (donepezil hydrochloride tablets). US package insert, December 2000. Teaneck, NJ: Eisai Inc.
14. Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998; 46(Suppl. 1): 19-24.
15. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 25-9.
16. Nagy CF, Kumar D, Perdomo CA, Wason S, Cullen EI, Pratt RD. Concurrent administration of donepezil HCL and Sertraline HCL in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol 2004; 58: 25-33.
17. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 30-4.
18. Oertel WH, Quinn NP. Parkinson's disease: drug therapy. Baillieres Clin Neurol 1997; 6: 89-108.
19. Levodopa. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists Inc.
20. Broe GA, Caird FI. Levodopa for parkinsonism in elderly and demented patients. Med J Aust 1973; 1: 630-5.
21. Height and Weight Standards. New York: Metropolitan Life Insurance Company, 1983.
22. Stacy M. Pharmacotherapy for advanced Parkinson's disease. Pharmacotherapy 2000; 20: 8S-16S.
23. Berchou RC. Maximizing the benefit of pharmacotherapy in Parkinson's disease. Pharmacotherapy 2000; 20: 33S-42S.
24. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996; 46: 1051-4.
25. Sage JI, Mark MH. Pharmacokinetics of continuous-release carbidopa/levodopa. Clin Neuropharmacol 1994; 17(Suppl. 2): S1-S6.
26. Evans MA, Broe GA, Triggs EJ, Cheung M, Creasey H, Paull PD. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 1981; 31: 1288-94.
27. Robertson DR, Wood ND, Everest H, Monks K, Waller DG, Renwick AG, George CF. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 1989; 28: 61-9.
28. Eriksson T, Granerus A, Linde A, Carlsson A. 'On-off' phenomenon in Parkinson's disease: relationship between dopa and other large neutral amino acids in plasma. Neurology 1988; 38: 1245-8.
29. Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 1991; 41: 463-6.
30. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 1-6.
31. Algeri S, Cerletti C, Curcio M, Morselli PL, Bonollo L, Buniva G, Minazzi M, Minoli G. Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and in man. Eur J Pharmacol 1976; 35: 293-9.
32. Merello M, Sabe L, Teson A, Migliorelli R, Petracchi M, Leiguarda R, Starkstein S. Extrapyramidalism in Alzheimer's disease: prevalence, psychiatric, and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1994; 57: 1503-1509.
33. Shea C, MacKnight C, Rockwood K. Donepezil for the treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998; 10: 229-38.
34. Aarsland D, Larsen JP, Janvin C, Stavanger KL. Donepezil treatment in Parkinson's disease with dementia. A double-blind, placebo-controlled crossover study. Neurology 2001; 56(Suppl. 3): P02.105.
35. Parkman HP, Trate DM, Knight LC, Brown KL, Maure AH, Fisher RS. Cholinergic effects on human gastric motility. Gut 1999; 45: 346-54.
36. Harder S, Baas H. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. Clin Pharmacol Ther 1998; 64: 183-91.